Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon Alfa-2b in High-Risk Smoldering Multiple Myeloma
ChiCTR2600124944Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropeginterferon alfa-2b in smoldering multiple myeloma (SMM), sponsored by Peking Union Medical College Hospital. Primary endpoint: objective remission rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on ChiCTR2600124944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124944.